EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma

Kazuyuki Numakura iD, Yuya Sekine, Shingo Hatakeyama, Yumina Muto, Ryuta Sobu, Mizuki Kobayashi, Hajime Sasagawa, Soki Kashima, Ryohei Yamamto, Taketoshi Nara, Hideo Akashi, Ryuji Tabata und 5 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Kazuyuki Numakura und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nivolumab plus ipilimumab (NIVO+IPI) is the first‐line treatment for patients with metastatic renal cell carcinoma (mRCC). Approximately 40% of patients achieve a durable response; however, 20% develop primary resistant disease (PRD) to NIVO+IPI, about which little is known in patients with mRCC. Therefore, this investigation aimed to evaluate the clinical implication of PRD in patients with mRCC to select better candidates in whom NIVO+IPI can be initiated as first‐line therapy.

Methods

This multi‐institutional retrospective cohort study used data collected between August 2015 and January 2023. In total, 120 patients with mRCC treated with NIVO+IPI were eligible. Associations between immune‐related adverse events and progression‐free survival, overall survival (OS), and objective response rate were analyzed. The relationship between other clinical factors and outcomes was also evaluated.

Results

The median observation period was 16 months (interquartile range, 5–27). The median age at NIVO+IPI initiation was 68 years in the male‐dominant population ( n = 86, 71.7%), and most patients had clear cell histology ( n = 104, 86.7%). PRD was recorded in 26 (23.4%) of 111 investigated patients during NIVO+IPI therapy. Patients who experienced PRD showed worse OS (hazard ratio: 4.525, 95% confidence interval [CI]: 2.315–8.850, p < 0.001). Multivariable analysis showed that lymph node metastasis (LNM) (odds ratio: 4.274, 95% CI: 1.075–16.949, p = 0.039) was an independent risk factor for PRD.

Conclusions

PRD was strongly correlated with worse survival rates. LNM was independently associated with PRD in patients with mRCC receiving NIVO+IPI as first‐line therapy and might indicate that a candidate will not benefit from NIVO+IPI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansMaleAgedNivolumabIpilimumabRetrospective StudiesAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

ipilimumablymph node metastasisneoplasm metastasisnivolumabrenal cell carcinomasurvival rate

Substanzen

NivolumabIpilimumab

Autor:innen und Institutionen

  • Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Department of Anatomy, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Urology, Ageo Central General Hospital, Ageo, Japan.

ORCID-Profile: Kazuyuki Numakura, Shintaro Narita

Zitieren

APA

Numakura, K., Sekine, Y., Hatakeyama, S., Muto, Y., Sobu, R., Kobayashi, M., Sasagawa, H., Kashima, S., Yamamto, R., Nara, T., Akashi, H., Tabata, R., Sato, S., Saito, M., Narita, S., Ohyama, C., & Habuchi, T. (2023). Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.6306

Vancouver

Numakura K, Sekine Y, Hatakeyama S, Muto Y, Sobu R, Kobayashi M, et al. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma. Cancer Medicine. 2023. doi:10.1002/cam4.6306

BibTeX
@article{Numakura2023,
  author = {Numakura, Kazuyuki and Sekine, Yuya and Hatakeyama, Shingo and Muto, Yumina and Sobu, Ryuta and Kobayashi, Mizuki and Sasagawa, Hajime and Kashima, Soki and Yamamto, Ryohei and Nara, Taketoshi and Akashi, Hideo and Tabata, Ryuji and Sato, Satoshi and Saito, Mitsuru and Narita, Shintaro and Ohyama, Chikara and Habuchi, Tomonori},
  title = {Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6306}
}
Kostenlos starten →